US7822557B2 - Analyte sensors and methods - Google Patents
Analyte sensors and methods Download PDFInfo
- Publication number
- US7822557B2 US7822557B2 US11/555,167 US55516706A US7822557B2 US 7822557 B2 US7822557 B2 US 7822557B2 US 55516706 A US55516706 A US 55516706A US 7822557 B2 US7822557 B2 US 7822557B2
- Authority
- US
- United States
- Prior art keywords
- analyte
- data collection
- sample
- charge
- electrolysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 239000012491 analyte Substances 0.000 title claims abstract description 65
- 238000000034 method Methods 0.000 title claims abstract description 55
- 238000013480 data collection Methods 0.000 claims abstract description 37
- 238000005868 electrolysis reaction Methods 0.000 claims abstract description 24
- 238000003869 coulometry Methods 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 238000004082 amperometric method Methods 0.000 claims description 4
- 238000004313 potentiometry Methods 0.000 claims description 2
- 238000005259 measurement Methods 0.000 description 19
- 239000000758 substrate Substances 0.000 description 14
- 238000013213 extrapolation Methods 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 238000005534 hematocrit Methods 0.000 description 6
- -1 CK-MB) Chemical compound 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000013060 biological fluid Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000007812 electrochemical assay Methods 0.000 description 2
- 239000012992 electron transfer agent Substances 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 102100038358 Prostate-specific antigen Human genes 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 238000006056 electrooxidation reaction Methods 0.000 description 1
- IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
- C12Q1/005—Enzyme electrodes involving specific analytes or enzymes
- C12Q1/006—Enzyme electrodes involving specific analytes or enzymes for glucose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
- G01N27/3271—Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood
- G01N27/3273—Devices therefor, e.g. test element readers, circuitry
Definitions
- This invention relates to methods for determining the concentration of an analyte in a sample, and sensors that incorporate those methods.
- Biosensors also referred to as analytical sensors or merely sensors, are commonly used to determine the presence and concentration of a biological analyte in a sample. Such biosensors are used, for example, to detect and monitor blood glucose levels in diabetic patients.
- the detection and quantification of the analyte level can be accomplished by, for example, coulometry, amperometry, potentiometry or any combination thereof.
- the analyte concentration is generally determined from the average amount of the current, in amps, measured over a predetermined time period.
- the analyte concentration is determined from an integrated total amount of the charge, in coulombs, measured over the period of time for required for substantial completion of sample electrolysis.
- the science of analyte determination is an area of ongoing development.
- the present disclosure provides methods for the determination of the end-point of sample collection for analyte sensors, and sensors configured to determine an analyte concentration in a sample using those methods.
- the techniques of the present disclosure apply to those determination methods in which the sample, such as in an analytic device, is entirely or substantially reacted during the time frame of the analysis.
- An obvious electrochemical example is coulometry, and certain photometric methods are also analogous.
- the techniques of the present disclosure extrapolate the total charge by continuously monitoring the measured charge and by continuously calculating the extrapolated and total charge, as well as the percent completion, as the reaction proceeds toward completion. These techniques determine a data collection endpoint based on a predetermined percentage of electrolysis of analyte, by comparing the measured charge to the total charge.
- the final measured signal (e.g., for coulometry the signal is charge) is typically the sum of two components, (1) the measured signal or that signal which is actually measured prior to the data collection endpoint, and (2) the extrapolated signal, or signal calculated or otherwise expected to occur after the data collection endpoint, by the process of extrapolation.
- the total signal is the sum of the measured signal and the extrapolated signal.
- the time of the data collection endpoint is the basis for determining the relative contributions of the measured and extrapolated signals, as well as the total signal.
- the data collection endpoint is determined from a percentage of electrolysis of analyte, rather than from a predetermined time period or from the fall of the current to a predetermined percentage of the initial value.
- the total charge is calculated from extrapolated current decay from a data collection endpoint in real time, that endpoint having been determined from a predicted total charge.
- the endpoint is at a predetermined percentage of the predicted total charge. The predicted total charge is used to control the current collection process until the point in time that a predetermined fraction of total analyte in the sample is electrolyzed. The method uses a fraction of the predicted total charge instead of using current or time for the determination of the data collection endpoint.
- Embodiments of the present invention are used for the detection and quantification of an analyte, for example glucose, from a sample; in many embodiments the detection and quantification is accomplished with a small volume, e.g., submicroliter sample.
- the sensor's sample chamber may be any suitable size, including large and small volume sample chambers.
- the sample chamber is sized to contain no more than about 1 ⁇ L (microliter) of sample, in some embodiments no more than about 0.5 ⁇ L, in some embodiments no more than about 0.25 ⁇ L, and in other embodiments no more than about 0.1 ⁇ L of sample, where in certain embodiments the sample chamber has a volume of no more than about 0.05 ⁇ L or even about 0.03 ⁇ L or less.
- Sensors of the present invention may include two substrates forming the overall sensor construction, a spacer between the substrates, at least one working electrode, at least one counter electrode, and other optional electrodes. Together, the two substrates and spacer define a sample chamber between the substrates. At least a portion of the working electrode(s) and counter electrode(s) are present in the sample chamber.
- the working electrode and counter electrode may be planar or facing each other.
- FIG. 1 is a graphical example of an analyte measurement, illustrating the general concepts of measured signal, extrapolated signal, and data collection endpoint.
- FIG. 2 is a graphical comparison of extrapolated current determined using a conventional extrapolation technique and extrapolation results using the techniques of the present disclosure.
- FIG. 3 is a schematic perspective view of a sensor suitable for use with the techniques of the present invention.
- FIG. 4 is an exploded view of the sensor strip shown in FIG. 3 , the layers illustrated individually.
- the present disclosure is directed to methods of calculating the total charge of an electrolysis reaction, and determining an analyte concentration based on that total charge.
- the disclosure is also directed to sensors or biosensors that utilize a calculation for determining the analyte concentration based on a fraction of the predicted total charge.
- Sensors are devices configured to detect the presence of and/or measure the concentration of an analyte in a sample via electrochemical oxidation and reduction reactions. These reactions are transduced to an electrical signal that can be correlated to an amount or concentration of analyte.
- a sensor may be configured as an elongated strip or otherwise.
- the senor is connected to an electrical device, to provide a meter coupled to the sensor.
- the meter is configured and arranged to determine, during electrolysis of a sample in the sample chamber, the total charge, usually from a series of current values.
- the meter is also configured to calculate the analyte concentration in the sample based on the total charge, total estimated charge or total calculated charge from the electrolysis of the analyte.
- coulometry is the electroanalytical technique used for the current and/or charge determination.
- coulometry has the disadvantage of requiring the volume of the sample be known
- coulometry is a preferred technique for the analysis of small samples (e.g., less than 1 microliter) because it has the advantages of, e.g., minimal temperature dependence for the measurement, minimal enzyme activity dependence for the measurement, minimal redox-mediator activity dependence for the measurement, and no error in the measurement from depletion of analyte in the sample.
- Coulometry is a method for determining the amount of charge passed or projected to pass during complete or nearly complete electrolysis of the analyte.
- One coulometric technique involves electrolyzing the analyte on a working electrode and measuring the resulting current between the working electrode and a counter electrode at two or more times during the electrolysis. The electrolysis is complete, i.e., 100% electrolyzed, when the current reaches a value near or at zero. The charge used to electrolyze the sample is then calculated by integrating the measured currents over time and accounting for any background signal. Because the charge is directly related to the amount of analyte in the sample there is no temperature dependence of the measurement.
- the activity of the enzyme does not affect the value of the measurement, but only the time required to obtain the measurement (i.e., less active enzyme requires a longer time to achieve complete electrolysis of the sample) so that decay of the enzyme over time will not render the analyte concentration determination inaccurate.
- analyte concentration has been determined through 100% electrolysis; that is, 100% of the analyte has been electrolyzed.
- the total charge measured from the electrolysis is related to the analyte concentration abiding Faraday's Law.
- the total charge can be determined from measurements of the electrolysis current, it, over time, t.
- a series of currents (i x , i x+1 , i x+2 , . . . ) is measured for a series of times (t x , t x+1 , t x+2 , . . . ).
- the current can then be integrated over time (e.g., numerically integrated using known numerical methods) to give the total charge.
- the analyte concentration is then calculated from the total charge.
- 100% electrolysis of the analyte could take up to tens of seconds or even more.
- some designs have the current measurements end after a period of time, e.g., after a predetermined period of time, or after the current has decreased to a predetermined percentage of its initial level, when only a fraction or percentage of the analyte has been electrolyzed.
- the subsequent current is calculated, i.e., extrapolated, from the measured current data.
- the total charge is then integrated from the measured current points and the extrapolated data, and analyte concentration is calculated from the total charge.
- Data extrapolation is usually based on a simplified mathematic model of the expected actual results.
- factors such as aged or deteriorated sensors, high analyte concentration, high hematocrit percentage, high sample viscosity, etc., that may cause the current decay profile to deviate from expected.
- the extrapolated total charge may vary substantially, depending on the time of the data collection endpoint.
- the methods of this disclosure utilize values that are directly related to the percentage of analyte being electrolyzed, rather than a predetermined time period of electrolysis.
- the methods utilize a percentage of the total charge to select a data collection endpoint, at which extrapolation begins.
- the methods of this disclosure predict the total charge from analyte electrolysis, take a predetermined percentage of that predicted total charge to find a data collection endpoint, and from the current at that predetermined data collection endpoint, extrapolate to determine the total charge. The extrapolated total charge is then correlated to an analyte concentration.
- the predicted total charge is used to control the data collecting process, until a time when a predetermined fraction or percentage of analyte in the sample has been electrolyzed.
- the method uses a fraction or percentage of the predicted total charge for the determination of the endpoint of data collection, which is directly related to the percentage of analyte being analyzed, instead of merely using time or current, as in previous methods. From the determined data collection endpoint, the total charge is extrapolated, which is then correlated to an analyte concentration.
- This calculation technique of the present disclosure is a better approach than previous extrapolation techniques, yielding more accurate concentration values and accommodating wider situations, e.g., hemocrit levels, sample temperature and/or viscosity, etc.
- Methods of this disclosure use a predicted total charge to determine the data collection endpoint. This prediction of total charge is done in ‘real time’, during the electrolysis of the analyte. The prediction can be done by using a regular or conventional data extrapolation algorithm, which generally includes numerous iterative approximation steps, which may require the use of a powerful microprocessor in the meter. Alternately, an approximated model can be used for predicting the total charge.
- a data collection endpoint is selected, based on a predetermined percentage of the electrolyzed analyte.
- the predetermined percentage can be any percentage greater than 0 (zero) up to 100%. In some embodiments, however, the measured percentage of total charge is at least 40%, and in other embodiments, at least 50%. That is, in some embodiments, at least 40% of the analyte has been electrolyzed at the data collection endpoint, and in other embodiments, at least 50% of the analyte has been electrolyzed.
- the underlying premise of the calculation technique of the present disclosure is to use a data collection endpoint that balances between the speed and accuracy of measurement, and which is directly related to the percentage of analyte being electrolyzed.
- a linear extrapolation based on the measured current data and the data collection endpoint, is used to calculate a linearly estimated current and thus a linearly estimated charge, Q lin .
- a portion of the measured current data usually only that collected, e.g, 1 or 2 seconds prior to the data collection endpoint, is used for the linear current estimate and the linearly estimated charge.
- the linearly estimated charge, Q lin is a percentage, p, of the extrapolated portion of the charge, Q e .
- the final Q e /Q total ratio is calculated by combining with the dynamic measured portion of charge Q m .
- FIG. 1 is a graphical example of an analyte measurement, illustrating the general concepts of measured signal, extrapolated signal, and data collection endpoint.
- FIG. 2 provides a graphical explanation of the methods of this disclosure using one specific example.
- the solid line beginning at time 0, represents the actual current measurement.
- I o the initial current
- the total current is extrapolated (dashed line) and a total charge is predicted.
- the predetermined electrolysis percentage is set at 50% of the predicted total charge.
- the data collection ends at this predetermined endpoint, which in this example is approximately 5 seconds.
- a linear extrapolation is made.
- the total charge is integrated over the extrapolated linear current and the measured current data. From the total charge, the analyte concentration is determined.
- the predetermined endpoint for data collection is no more than about 10 seconds, in some embodiments no more than about 5 seconds, and in some embodiments, no more than about 3 seconds.
- FIGS. 3-4 one example of an in vitro electrochemical sensor suitable for use with the invention is schematically illustrated. It is understood that the analyte measurement procedure of this disclosure could be used with any sensor configuration, and that the sensor strip illustrated in the figures is representative of only one suitable sensor.
- FIGS. 3-4 an exemplary embodiment of a sensor, suitable for use with the end-point determination methods of the present disclosure, is schematically illustrated, herein shown in the shape of a sensor strip 10 .
- Sensor strip 10 has a first substrate 12 , a second substrate 14 , and a spacer 15 positioned therebetween. Together, these elements define, at least partially, a sample chamber 20 with an inlet 21 for receiving a sample to be analyzed.
- the sample chamber is sized to contain no more than about 1 ⁇ L (microliter) of sample, in some embodiments no more than about 0.5 ⁇ L, in some embodiments no more than about 0.25 ⁇ L, and in other embodiments no more than about 0.1 ⁇ L of sample, where in certain embodiments the sample chamber has a volume of no more than about 0.05 ⁇ L or even about 0.03 ⁇ L or less.
- Sample chamber 20 includes a measurement zone where the sample is electrolyzed.
- the measurement zone is sized to contain no more than about 1 ⁇ L of sample, in some embodiments no more than about 0.5 ⁇ L, in some embodiments no more than about 0.25 ⁇ L, and in other embodiments no more than about 0.1 ⁇ L of sample, where in certain embodiments the measurement zone has a volume of no more than about 0.05 ⁇ L or even about 0.03 ⁇ L or less.
- Sensor strip 10 includes at least one working electrode 22 and at least one counter electrode 24 .
- Sensor strip 10 has a first, distal end 10 A and an opposite, proximal end 10 B.
- sample to be analyzed is applied to sensor 10 .
- Distal end 10 A could be referred as ‘the fill end’, ‘sample receiving end’, or similar.
- Inlet 21 is positioned at or proximate to distal end 10 A.
- Proximal end 10 B of sensor 10 is configured for operable, and usually releasable, connecting to a device such as a meter.
- Sensor strip 10 is a layered construction, in certain embodiments having a generally rectangular shape, i.e., its length is longer than its width, although other shapes of sensor 10 are possible as well.
- substrates 12 , 14 can be inert substrates (e.g., polymeric substrates), although other substrates can be used.
- Electrodes 22 , 24 and any other electrodes, generally comprise a conductive material, such as carbon, silver, gold, platinum, or the like.
- electrodes 22 , 24 are facing electrodes, positioned generally opposite one another on separate substrates 12 , 14 .
- Alternate embodiments of sensors can have electrodes 22 , 24 on the same substrate, e.g., as co-planar or planar electrodes.
- sensing chemistry material(s) are provided in sample chamber 20 to facilitate the analysis of the analyte.
- Sensing chemistry material facilitates the transfer of electrons between working electrode 22 and the analyte in the sample.
- Any sensing chemistry may be used in sensor strip 10 , and the sensing chemistry may include one or more materials.
- the sensing chemistry generally includes an electron transfer agent that facilitates the transfer of electrons to or from the analyte.
- the sensing chemistry may, additionally to or alternatively to the electron transfer agent, include a redox mediator.
- a sample of biological fluid is provided into sample chamber 20 of sensor 10 , where the level of analyte is determined using the methods described above. In many embodiments, it is the level of glucose in blood, interstitial fluid, and the like, that is determined. Also in many embodiments, the source of the biological fluid is a drop of blood drawn from a patient, e.g., after piercing the patient's skin with a lancing device or the like, which may be present in an integrated device, together with the sensor strip.
- Embodiments of the subject methods include contacting the sensor with a fluid sample (obtained, e.g., from a skin incision) and transferring a volume of the fluid to the sample chamber and measurement zone of the sensor. Accordingly, bodily fluid may be first contacted with a portion of one of the substrates of the sensor prior to being contacted with the other substrate and/or sample chamber.
- a fluid sample obtained, e.g., from a skin incision
- a common use for an analyte sensor of the present invention, such as sensor 10 is for the determination of analyte concentration in a biological fluid, such as glucose concentration in blood, interstitial fluid, and the like, in a patient or other user.
- Additional analytes include but are not limited to, for example, acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., CK-MB), creatine, DNA, fructosamine, glucose, glutamine, growth hormones, hormones, ketones, lactate, peroxide, prostate-specific antigen, prothrombin, RNA, thyroid stimulating hormone, and troponin.
- concentration of drugs such as, for example, antibiotics (e.g., gentamicin, vancomycin, and the like), digitoxin, digoxin, drugs of abuse, theophylline, and warfarin, may also be determined.
- Sensor strips 10 may be available at pharmacies, hospitals, clinics, from doctors, and other sources of medical devices. Multiple sensor strips 10 may be packaged together and sold as a single unit; e.g., a package of about 25, about 50, or about 100 sensors, or any other suitable number.
- a kit may include one or more sensors of the present invention, and additional components such as control solutions and/or lancing device and/or meter, etc.
- Sensor strips 10 may be used for an electrochemical assay, or, for a photometric test. Sensor strips 10 are generally configured for use with an electrical meter, which may be connectable to various electronics. A meter may be available at generally the same locations as sensor strips 10 , and sometimes may be packaged together with sensor strips 10 , e.g., as a kit.
- Suitable electronics connectable to the meter include a data processing terminal, such as a personal computer (PC), a portable computer such as a laptop or a handheld device (e.g., personal digital assistants (PDAs)), and the like.
- the electronics are configured for data communication with the receiver via a wired or a wireless connection. Additionally, the electronics may further be connected to a data network (not shown) for storing, retrieving and updating data corresponding to the detected glucose level of the user.
- the various devices connected to the meter may wirelessly communicate with a server device, e.g., using a common standard such as 802.11 or Bluetooth RF protocol, or an IrDA infrared protocol.
- the server device could be another portable device, such as a Personal Digital Assistant (PDA) or notebook computer, or a larger device such as a desktop computer, appliance, etc.
- PDA Personal Digital Assistant
- the server device has a display, such as a liquid crystal display (LCD), as well as an input device, such as buttons, a keyboard, mouse or touch-screen.
- the user can control the meter indirectly by interacting with the user interface(s) of the server device, which in turn interacts with the meter across a wireless link.
- the server device may also communicate with another device, such as for sending data from the meter and/or the service device to a data storage or computer.
- the service device could send and/or receive instructions (e.g., an insulin pump protocol) from a health care provider computer.
- instructions e.g., an insulin pump protocol
- Examples of such communications include a PDA synching data with a personal computer (PC), a mobile phone communicating over a cellular network with a computer at the other end, or a household appliance communicating with a computer system at a physician's office.
- a lancing device or other mechanism to obtain a sample of biological fluid, e.g., blood, from the patient or user may also be available at generally the same locations as sensor strips 10 and the meter, and sometimes may be packaged together with sensor strips 10 and/or meter, e.g., as a kit.
- Sensor strips 10 are particularly suited for inclusion in an integrated device, i.e., a device which has the sensor and a second element, such as a meter or a lancing device, in the device.
- the integrated device may be based on providing an electrochemical assay or a photometric assay.
- sensor strips 10 may be integrated with both a meter and a lancing device. Having multiple elements together in one device reduces the number of devices needed to obtain an analyte level and facilitates the sampling process.
- embodiments may include a housing that includes one or more of the subject strips, a skin piercing element and a processor for determining the concentration of an analyte in a sample applied to the strip.
- a plurality of strips 10 may be retained in a cassette in the housing interior and, upon actuation by a user, a single strip 10 may be dispensed from the cassette so that at least a portion extends out of the housing for use.
- Blood samples from eight different donors were adjust to five different hematocrit levels and tested with sensors.
- the results from the 40% hematocrit samples from the first two donors were used to determine calibration curves of the strips which were then application to all the rest of the data.
- the following table compares the results from using the sensor strips with an “old algorithm” based on end point determined by percent residue current and with the “new algorithm” which is based on a revised data collection endpoint.
- the data collection endpoint was when the current reading was 50% of the peak reading.
- the data collection endpoint was when 60% of the analyte had been electrolyzed.
- the coefficient ⁇ was 3.5.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Electrochemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
hematocrit |
| Algorithm | 15% | 25% | 40% | 55% | 65% | |
50 mg/dl | Old | 7.49 | 4.24 | 1.19 | 4.88 | 5.54 |
New | 3.17 | 0.21 | 1.56 | 2.25 | 0.40 | |
Δ | −4.02 | −4.03 | 0.37 | −2.62 | −5.14 | |
200 mg/dL | Old | 21.01 | 13.28 | −1.14 | −11.60 | −11.92 |
New | 19.80 | 12.03 | −2.14 | −7.57 | −5.77 | |
Δ | −1.21 | −1.25 | 1.00 | −4.03 | −6.15 | |
400 mg/dL | Old | 21.89 | 11.73 | −1.10 | −16.34 | −19.04 |
new | 21.79 | 11.54 | −1.24 | −11.94 | −8.17 | |
Δ | −0.10 | −0.19 | 0.14 | −4.40 | −10.87 | |
The negative signs represent a reduction in average bias, which is desirable. |
Claims (8)
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/555,167 US7822557B2 (en) | 2006-10-31 | 2006-10-31 | Analyte sensors and methods |
EP07852508A EP2092329A1 (en) | 2006-10-31 | 2007-10-03 | Analyte sensors and methods |
PCT/US2007/021229 WO2008054608A1 (en) | 2006-10-31 | 2007-10-03 | Analyte sensors and methods |
CNA2007800488992A CN101573616A (en) | 2006-10-31 | 2007-10-03 | Analyte sensors and methods |
CA002667982A CA2667982A1 (en) | 2006-10-31 | 2007-10-03 | Analyte sensors and methods |
US12/463,219 US7966131B2 (en) | 2006-10-31 | 2009-05-08 | Analyte sensors and methods |
US13/105,403 US8972198B2 (en) | 2006-10-31 | 2011-05-11 | Analyte sensors and methods |
US14/635,803 US20150168332A1 (en) | 2006-10-31 | 2015-03-02 | Analyte Sensors and Methods |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/555,167 US7822557B2 (en) | 2006-10-31 | 2006-10-31 | Analyte sensors and methods |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/463,219 Continuation US7966131B2 (en) | 2006-10-31 | 2009-05-08 | Analyte sensors and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
US20080102441A1 US20080102441A1 (en) | 2008-05-01 |
US7822557B2 true US7822557B2 (en) | 2010-10-26 |
Family
ID=39145314
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/555,167 Active 2029-02-08 US7822557B2 (en) | 2006-10-31 | 2006-10-31 | Analyte sensors and methods |
US12/463,219 Active US7966131B2 (en) | 2006-10-31 | 2009-05-08 | Analyte sensors and methods |
US13/105,403 Active 2029-06-23 US8972198B2 (en) | 2006-10-31 | 2011-05-11 | Analyte sensors and methods |
US14/635,803 Abandoned US20150168332A1 (en) | 2006-10-31 | 2015-03-02 | Analyte Sensors and Methods |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/463,219 Active US7966131B2 (en) | 2006-10-31 | 2009-05-08 | Analyte sensors and methods |
US13/105,403 Active 2029-06-23 US8972198B2 (en) | 2006-10-31 | 2011-05-11 | Analyte sensors and methods |
US14/635,803 Abandoned US20150168332A1 (en) | 2006-10-31 | 2015-03-02 | Analyte Sensors and Methods |
Country Status (5)
Country | Link |
---|---|
US (4) | US7822557B2 (en) |
EP (1) | EP2092329A1 (en) |
CN (1) | CN101573616A (en) |
CA (1) | CA2667982A1 (en) |
WO (1) | WO2008054608A1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110231105A1 (en) * | 2010-03-22 | 2011-09-22 | Bayer Healthcare Llc | Residual Compensation Including Underfill Error |
WO2013163342A1 (en) | 2012-04-24 | 2013-10-31 | Abbott Diabetes Care Inc. | Methods of lag-compensation for analyte measurements, and devices related thereto |
WO2016205378A1 (en) | 2015-06-15 | 2016-12-22 | Abbott Diabetes Care Inc. | Stabilized lactate responsive enzymes, electrodes and sensors, and methods for making and using the same |
WO2017011346A1 (en) | 2015-07-10 | 2017-01-19 | Abbott Diabetes Care Inc. | System, device and method of dynamic glucose profile response to physiological parameters |
WO2017151952A1 (en) | 2016-03-04 | 2017-09-08 | Abbott Diabetes Care Inc. | Nad(p)-dependent responsive enzymes, electrodes and sensors, and methods for making and using the same |
US10004439B2 (en) | 2012-09-21 | 2018-06-26 | Abbott Diabetes Care Inc. | In vivo sensors having ceria nanoparticle electrodes |
US10010273B2 (en) | 2011-03-10 | 2018-07-03 | Abbott Diabetes Care, Inc. | Multi-function analyte monitor device and methods of use |
EP3381360A1 (en) | 2011-09-28 | 2018-10-03 | Abbott Diabetes Care, Inc. | Methods, devices and systems for analyte monitoring management |
US10330666B2 (en) | 2014-03-07 | 2019-06-25 | Ascensia Diabetes Care Holdings Ag | Biosensor calibration coding systems and methods |
US10598624B2 (en) | 2014-10-23 | 2020-03-24 | Abbott Diabetes Care Inc. | Electrodes having at least one sensing structure and methods for making and using the same |
US10888272B2 (en) | 2015-07-10 | 2021-01-12 | Abbott Diabetes Care Inc. | Systems, devices, and methods for meal information collection, meal assessment, and analyte data correlation |
WO2022164940A1 (en) | 2021-01-26 | 2022-08-04 | Abbott Diabetes Care Inc. | Systems, devices, and methods related to ketone sensors |
WO2023110190A1 (en) | 2021-12-13 | 2023-06-22 | Heraeus Medical Gmbh | Tests and methods for detecting bacterial infection |
USD1015366S1 (en) | 2020-07-29 | 2024-02-20 | Abbott Diabetes Care Inc. | Display screen or portion thereof with graphical user interface |
EP4357778A1 (en) | 2022-10-20 | 2024-04-24 | Heraeus Medical GmbH | Treatment of microbial infections diagnosed using the biomarker d-lactate |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190357827A1 (en) | 2003-08-01 | 2019-11-28 | Dexcom, Inc. | Analyte sensor |
RU2006132051A (en) | 2004-02-06 | 2008-03-20 | БАЙЕР ХЕЛТКЭР ЭлЭлСи (US) | OXIDIZABLE COMPOUNDS AS AN INTERNAL STANDARD FOR BIOSENSORS AND METHOD OF APPLICATION |
US9572534B2 (en) | 2010-06-29 | 2017-02-21 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US10226207B2 (en) | 2004-12-29 | 2019-03-12 | Abbott Diabetes Care Inc. | Sensor inserter having introducer |
US9636450B2 (en) | 2007-02-19 | 2017-05-02 | Udo Hoss | Pump system modular components for delivering medication and analyte sensing at seperate insertion sites |
US7697967B2 (en) | 2005-12-28 | 2010-04-13 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US9788771B2 (en) | 2006-10-23 | 2017-10-17 | Abbott Diabetes Care Inc. | Variable speed sensor insertion devices and methods of use |
CA2986870A1 (en) | 2005-09-30 | 2007-04-12 | Ascensia Diabetes Care Holdings Ag | Gated voltammetry |
US11298058B2 (en) | 2005-12-28 | 2022-04-12 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US7885698B2 (en) | 2006-02-28 | 2011-02-08 | Abbott Diabetes Care Inc. | Method and system for providing continuous calibration of implantable analyte sensors |
US8224415B2 (en) | 2009-01-29 | 2012-07-17 | Abbott Diabetes Care Inc. | Method and device for providing offset model based calibration for analyte sensor |
US9675290B2 (en) | 2012-10-30 | 2017-06-13 | Abbott Diabetes Care Inc. | Sensitivity calibration of in vivo sensors used to measure analyte concentration |
US8219173B2 (en) | 2008-09-30 | 2012-07-10 | Abbott Diabetes Care Inc. | Optimizing analyte sensor calibration |
JP2010508091A (en) | 2006-10-26 | 2010-03-18 | アボット ダイアベティス ケア インコーポレイテッド | Method, system, and computer program product for detecting in real time a decrease in sensitivity of an analyte sensor |
CA2690742C (en) | 2007-06-21 | 2018-05-15 | Abbott Diabetes Care Inc. | Health management devices and methods |
US8160900B2 (en) | 2007-06-29 | 2012-04-17 | Abbott Diabetes Care Inc. | Analyte monitoring and management device and method to analyze the frequency of user interaction with the device |
EP2176652B1 (en) * | 2007-07-26 | 2014-04-23 | Nipro Diagnostics, Inc. | System and methods for determination of analyte concentration using time resolved amperometry |
US8101062B2 (en) * | 2007-07-26 | 2012-01-24 | Nipro Diagnostics, Inc. | System and methods for determination of analyte concentration using time resolved amperometry |
WO2009076302A1 (en) | 2007-12-10 | 2009-06-18 | Bayer Healthcare Llc | Control markers for auto-detection of control solution and methods of use |
US9143569B2 (en) | 2008-02-21 | 2015-09-22 | Dexcom, Inc. | Systems and methods for processing, transmitting and displaying sensor data |
US8924159B2 (en) | 2008-05-30 | 2014-12-30 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US8591410B2 (en) | 2008-05-30 | 2013-11-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
CN105353013B (en) | 2008-07-10 | 2020-01-14 | 安晟信医疗科技控股公司 | Method for identifying ionized species in a sample |
WO2010009172A1 (en) | 2008-07-14 | 2010-01-21 | Abbott Diabetes Care Inc. | Closed loop control system interface and methods |
US7896703B2 (en) * | 2008-07-17 | 2011-03-01 | Abbott Diabetes Care Inc. | Strip connectors for measurement devices |
GB0814238D0 (en) * | 2008-08-04 | 2008-09-10 | Oxford Biosensors Ltd | Enhancement of electrochemical response |
EP2341829A4 (en) | 2008-10-03 | 2012-11-28 | Abbott Diabetes Care Inc | Integrated lancet and analyte testing apparatus |
US9326707B2 (en) | 2008-11-10 | 2016-05-03 | Abbott Diabetes Care Inc. | Alarm characterization for analyte monitoring devices and systems |
US20100198034A1 (en) | 2009-02-03 | 2010-08-05 | Abbott Diabetes Care Inc. | Compact On-Body Physiological Monitoring Devices and Methods Thereof |
US20100198188A1 (en) * | 2009-02-05 | 2010-08-05 | Abbott Diabetes Care Inc. | Devices and Methods for Metering Insoluble Active Agent Particles |
US8758583B2 (en) | 2009-04-28 | 2014-06-24 | Abbott Diabetes Care Inc. | Smart sensor ports and methods of using same |
EP2434944B1 (en) | 2009-05-29 | 2014-12-03 | Abbott Diabetes Care, Inc. | Glucose monitoring system with wireless communications |
US9184490B2 (en) | 2009-05-29 | 2015-11-10 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
EP2438527B1 (en) | 2009-06-04 | 2018-05-02 | Abbott Diabetes Care, Inc. | Method and system for updating a medical device |
LT3689237T (en) | 2009-07-23 | 2021-09-27 | Abbott Diabetes Care, Inc. | Method of manufacturing and system for continuous analyte measurement |
US9125603B2 (en) | 2009-08-11 | 2015-09-08 | Abbott Diabetes Care Inc. | Analyte sensor ports |
US20110040208A1 (en) * | 2009-08-11 | 2011-02-17 | Abbott Diabetes Care Inc. | Integrated lancet and test strip and methods of making and using same |
WO2011025549A1 (en) | 2009-08-31 | 2011-03-03 | Abbott Diabetes Care Inc. | Medical devices and methods |
US8357276B2 (en) | 2009-08-31 | 2013-01-22 | Abbott Diabetes Care Inc. | Small volume test strips with large sample fill ports, supported test strips, and methods of making and using same |
WO2011053881A1 (en) | 2009-10-30 | 2011-05-05 | Abbott Diabetes Care Inc. | Method and apparatus for detecting false hypoglycemic conditions |
US8828330B2 (en) * | 2010-01-28 | 2014-09-09 | Abbott Diabetes Care Inc. | Universal test strip port |
US9041730B2 (en) | 2010-02-12 | 2015-05-26 | Dexcom, Inc. | Receivers for analyzing and displaying sensor data |
CA3135001A1 (en) | 2010-03-24 | 2011-09-29 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US8919607B2 (en) | 2010-04-16 | 2014-12-30 | Abbott Diabetes Care Inc. | Analyte test strip vial |
US9320432B2 (en) | 2010-04-16 | 2016-04-26 | Abbott Diabetes Care Inc. | Analyte meter communication module |
WO2011149857A1 (en) | 2010-05-24 | 2011-12-01 | Abbott Diabetes Care Inc. | Method and system for updating a medical device |
US11064921B2 (en) | 2010-06-29 | 2021-07-20 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US10092229B2 (en) | 2010-06-29 | 2018-10-09 | Abbott Diabetes Care Inc. | Calibration of analyte measurement system |
DK2598021T3 (en) | 2010-07-28 | 2015-09-28 | Abbott Diabetes Care Inc | Analyte sensors with temperature-independent membranes |
US8757386B2 (en) | 2010-09-30 | 2014-06-24 | Abbott Diabetes Care Inc. | Analyte test strip containers and inserts |
EP2633310A4 (en) | 2010-10-26 | 2016-02-24 | Abbott Diabetes Care Inc | Analyte measurement devices and systems, and components and methods related thereto |
US8702928B2 (en) | 2010-11-22 | 2014-04-22 | Abbott Diabetes Care Inc. | Modular analyte measurement system with extendable strip port |
US9713440B2 (en) | 2010-12-08 | 2017-07-25 | Abbott Diabetes Care Inc. | Modular analyte measurement systems, modular components thereof and related methods |
EP4397242A3 (en) | 2010-12-09 | 2024-08-28 | Abbott Diabetes Care Inc. | Analyte sensors with a sensing surface having small sensing spots |
US9760679B2 (en) | 2011-02-11 | 2017-09-12 | Abbott Diabetes Care Inc. | Data synchronization between two or more analyte detecting devices in a database |
WO2012108938A1 (en) | 2011-02-11 | 2012-08-16 | Abbott Diabetes Care Inc. | Software applications residing on handheld analyte determining devices |
WO2012108939A1 (en) | 2011-02-11 | 2012-08-16 | Abbott Diabetes Care Inc. | Feedback from cloud or hcp to payer or patient via meter or cell phone |
US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
CA3177983A1 (en) | 2011-02-28 | 2012-11-15 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
EP3825694B1 (en) | 2011-04-15 | 2023-10-25 | DexCom, Inc. | Advanced analyte sensor calibration and error detection |
EP2699175A4 (en) | 2011-04-20 | 2014-08-13 | Abbott Diabetes Care Inc | Analyte monitoring devices and methods |
EP2720612B1 (en) | 2011-06-16 | 2019-02-06 | Abbott Diabetes Care, Inc. | Temperature-compensated analyte monitoring devices, systems, and methods thereof |
WO2013003735A1 (en) | 2011-06-30 | 2013-01-03 | Abbott Diabetes Care Inc. | Methods for generating hybrid analyte level output, and devices and systems related thereto |
US9113833B2 (en) | 2011-08-16 | 2015-08-25 | Instrumentation Laboratory Company | System and method of increasing sample throughput |
US8560251B2 (en) | 2011-08-16 | 2013-10-15 | Instrumentation Laboratory Company | System and method of increasing sample throughput by estimation of a sensor endpoint |
WO2013049381A1 (en) | 2011-09-28 | 2013-04-04 | Abbott Diabetes Care Inc. | Methods for analyte monitoring management and analyte measurement data management, and articles of manufacture related thereto |
USD680454S1 (en) | 2011-10-25 | 2013-04-23 | Abbott Diabetes Care Inc. | Analyte meter and strip port |
WO2013066849A1 (en) | 2011-10-31 | 2013-05-10 | Abbott Diabetes Care Inc. | Model based variable risk false glucose threshold alarm prevention mechanism |
US8887911B2 (en) | 2011-12-09 | 2014-11-18 | Abbott Diabetes Care Inc. | Packages and kits for analyte monitoring devices, and methods related thereto |
US9535027B2 (en) | 2012-07-25 | 2017-01-03 | Abbott Diabetes Care Inc. | Analyte sensors and methods of using same |
WO2014052136A1 (en) | 2012-09-26 | 2014-04-03 | Abbott Diabetes Care Inc. | Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data |
EP2935615B1 (en) | 2012-12-21 | 2018-03-07 | Abbott Diabetes Care, Inc. | Method for improving measurement accuracy and devices and systems related thereto |
US9474475B1 (en) | 2013-03-15 | 2016-10-25 | Abbott Diabetes Care Inc. | Multi-rate analyte sensor data collection with sample rate configurable signal processing |
US10076285B2 (en) | 2013-03-15 | 2018-09-18 | Abbott Diabetes Care Inc. | Sensor fault detection using analyte sensor data pattern comparison |
AU2014233435A1 (en) | 2013-03-15 | 2015-09-03 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
US10433773B1 (en) | 2013-03-15 | 2019-10-08 | Abbott Diabetes Care Inc. | Noise rejection methods and apparatus for sparsely sampled analyte sensor data |
WO2014179343A1 (en) | 2013-04-30 | 2014-11-06 | Abbott Diabetes Care Inc. | Systems, devices, and methods for energy efficient electrical device activation |
AU2014374361B9 (en) | 2013-12-31 | 2019-07-04 | Abbott Diabetes Care Inc. | Self-powered analyte sensor and devices using the same |
WO2015153482A1 (en) | 2014-03-30 | 2015-10-08 | Abbott Diabetes Care Inc. | Method and apparatus for determining meal start and peak events in analyte monitoring systems |
US9904890B2 (en) | 2015-03-13 | 2018-02-27 | Instrumentation Laboratory Company | Detecting a transient error in a body fluid sample |
US10602988B2 (en) | 2016-03-21 | 2020-03-31 | International Business Machines Corporation | Obtainment of cleaned sequences relating to a center of gravity |
WO2018136898A1 (en) | 2017-01-23 | 2018-07-26 | Abbott Diabetes Care Inc. | Systems, devices and methods for analyte sensor insertion |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
US20190120785A1 (en) | 2017-10-24 | 2019-04-25 | Dexcom, Inc. | Pre-connected analyte sensors |
KR102095959B1 (en) * | 2018-07-11 | 2020-04-01 | 주식회사 아이센스 | Artificial Neural Network Model-Based Methods for Analyte Analysis |
US20210347926A1 (en) | 2018-09-18 | 2021-11-11 | I-Sens, Inc. | Oxidation-reduction polymer including transition metal complex, and electrochemical biosensor using same |
EP4203819B1 (en) | 2020-08-31 | 2024-07-31 | Abbott Diabetes Care Inc. | Systems, devices, and methods for analyte sensor insertion |
US20230041320A1 (en) * | 2021-08-03 | 2023-02-09 | Polymer Technology Systems, Inc. | Systems and Methods for Quantifying The Specific Activity of Creatininase |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5620466A (en) * | 1995-08-14 | 1997-04-15 | Cardiac Pacemakers, Inc. | Digital AGC using separate gain control and threshold templating |
US5824936A (en) * | 1997-01-17 | 1998-10-20 | Crystal Semiconductor Corporation | Apparatus and method for approximating an exponential decay in a sound synthesizer |
US6120676A (en) | 1997-02-06 | 2000-09-19 | Therasense, Inc. | Method of using a small volume in vitro analyte sensor |
US6338790B1 (en) | 1998-10-08 | 2002-01-15 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
US20020053523A1 (en) | 1999-11-04 | 2002-05-09 | Therasense, Inc. | Small volume in vitro analyte sensor and methods |
US6444115B1 (en) | 2000-07-14 | 2002-09-03 | Lifescan, Inc. | Electrochemical method for measuring chemical reaction rates |
US6579690B1 (en) | 1997-12-05 | 2003-06-17 | Therasense, Inc. | Blood analyte monitoring through subcutaneous measurement |
US20040079652A1 (en) | 2002-08-27 | 2004-04-29 | Bayer Healthcare Llc | Methods of determining glucose concentration in whole blood samples |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6134461A (en) * | 1998-03-04 | 2000-10-17 | E. Heller & Company | Electrochemical analyte |
-
2006
- 2006-10-31 US US11/555,167 patent/US7822557B2/en active Active
-
2007
- 2007-10-03 EP EP07852508A patent/EP2092329A1/en not_active Withdrawn
- 2007-10-03 WO PCT/US2007/021229 patent/WO2008054608A1/en active Application Filing
- 2007-10-03 CA CA002667982A patent/CA2667982A1/en not_active Abandoned
- 2007-10-03 CN CNA2007800488992A patent/CN101573616A/en active Pending
-
2009
- 2009-05-08 US US12/463,219 patent/US7966131B2/en active Active
-
2011
- 2011-05-11 US US13/105,403 patent/US8972198B2/en active Active
-
2015
- 2015-03-02 US US14/635,803 patent/US20150168332A1/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5620466A (en) * | 1995-08-14 | 1997-04-15 | Cardiac Pacemakers, Inc. | Digital AGC using separate gain control and threshold templating |
US5824936A (en) * | 1997-01-17 | 1998-10-20 | Crystal Semiconductor Corporation | Apparatus and method for approximating an exponential decay in a sound synthesizer |
US6120676A (en) | 1997-02-06 | 2000-09-19 | Therasense, Inc. | Method of using a small volume in vitro analyte sensor |
US6579690B1 (en) | 1997-12-05 | 2003-06-17 | Therasense, Inc. | Blood analyte monitoring through subcutaneous measurement |
US6338790B1 (en) | 1998-10-08 | 2002-01-15 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
US20060169599A1 (en) * | 1998-10-08 | 2006-08-03 | Therasense, Inc. | Small volume in vitro analyte sensor |
US20020053523A1 (en) | 1999-11-04 | 2002-05-09 | Therasense, Inc. | Small volume in vitro analyte sensor and methods |
US20020148739A2 (en) * | 1999-11-04 | 2002-10-17 | Therasense, Inc. | Small Volume in Vitro Analyte Sensor and Methods |
US6444115B1 (en) | 2000-07-14 | 2002-09-03 | Lifescan, Inc. | Electrochemical method for measuring chemical reaction rates |
US20040079652A1 (en) | 2002-08-27 | 2004-04-29 | Bayer Healthcare Llc | Methods of determining glucose concentration in whole blood samples |
Non-Patent Citations (1)
Title |
---|
Wang et al. Database Caplus DN: 96:154502. (Analytical Chemistry, 1982, 54(5), 861-964). * |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110231105A1 (en) * | 2010-03-22 | 2011-09-22 | Bayer Healthcare Llc | Residual Compensation Including Underfill Error |
US10591436B2 (en) | 2010-03-22 | 2020-03-17 | Ascensia Diabetes Care Holdings Ag | Residual compensation including underfill error |
US10010273B2 (en) | 2011-03-10 | 2018-07-03 | Abbott Diabetes Care, Inc. | Multi-function analyte monitor device and methods of use |
US12121350B2 (en) | 2011-03-10 | 2024-10-22 | Abbott Diabetes Care Inc. | Multi-function analyte monitor device and methods of use |
US12102428B2 (en) | 2011-09-28 | 2024-10-01 | Abbott Diabetes Care Inc. | Methods, devices and systems for analyte monitoring management |
EP3381360A1 (en) | 2011-09-28 | 2018-10-03 | Abbott Diabetes Care, Inc. | Methods, devices and systems for analyte monitoring management |
EP4060673A1 (en) | 2011-09-28 | 2022-09-21 | Abbott Diabetes Care, Inc. | Methods, devices and systems for analyte monitoring management |
US11087868B2 (en) | 2011-09-28 | 2021-08-10 | Abbott Diabetes Care Inc. | Methods, devices and systems for analyte monitoring management |
EP4541272A2 (en) | 2012-04-24 | 2025-04-23 | Abbott Diabetes Care, Inc. | Methods of lag-compensation for analyte measurements, and devices related thereto |
US9462970B2 (en) | 2012-04-24 | 2016-10-11 | Abbott Diabetes Care Inc. | Methods of lag-compensation for analyte measurements, and devices related thereto |
EP3777664A1 (en) | 2012-04-24 | 2021-02-17 | Abbott Diabetes Care, Inc. | Methods of lag-compensation for analyte measurements, and devices related thereto thereto |
US10561372B2 (en) | 2012-04-24 | 2020-02-18 | Abbott Diabetes Care Inc. | Methods of lag-compensation for analyte measurements, and devices related thereto |
WO2013163342A1 (en) | 2012-04-24 | 2013-10-31 | Abbott Diabetes Care Inc. | Methods of lag-compensation for analyte measurements, and devices related thereto |
US10004439B2 (en) | 2012-09-21 | 2018-06-26 | Abbott Diabetes Care Inc. | In vivo sensors having ceria nanoparticle electrodes |
US10006880B2 (en) | 2012-09-21 | 2018-06-26 | Abbott Diabetes Care Inc. | Test strips having ceria nanoparticle electrodes |
US11499960B2 (en) | 2014-03-07 | 2022-11-15 | Ascensia Diabetes Care Holdings Ag | Biosensor calibration coding systems and methods |
US10928379B2 (en) | 2014-03-07 | 2021-02-23 | Ascensia Diabetes Care Holdings Ag | Biosensor calibration coding systems and methods |
US10488395B2 (en) | 2014-03-07 | 2019-11-26 | Ascensia Diabetes Care Holdings Ag | Biosensor calibration coding systems and methods |
US10330666B2 (en) | 2014-03-07 | 2019-06-25 | Ascensia Diabetes Care Holdings Ag | Biosensor calibration coding systems and methods |
US11300537B2 (en) | 2014-10-23 | 2022-04-12 | Abbott Diabetes Care Inc. | Electrodes having at least one sensing structure and methods for making and using the same |
US10598624B2 (en) | 2014-10-23 | 2020-03-24 | Abbott Diabetes Care Inc. | Electrodes having at least one sensing structure and methods for making and using the same |
US9914952B2 (en) | 2015-06-15 | 2018-03-13 | Abbott Diabetes Care, Inc. | Stabilized lactate responsive enzymes, electrodes and sensors, and methods for making and using the same |
EP3967227A1 (en) | 2015-06-15 | 2022-03-16 | Abbott Diabetes Care Inc. | Stabilized lactate responsive enzymes, electrodes and sensors, and methods for making and using the same |
WO2016205378A1 (en) | 2015-06-15 | 2016-12-22 | Abbott Diabetes Care Inc. | Stabilized lactate responsive enzymes, electrodes and sensors, and methods for making and using the same |
WO2017011346A1 (en) | 2015-07-10 | 2017-01-19 | Abbott Diabetes Care Inc. | System, device and method of dynamic glucose profile response to physiological parameters |
US10888272B2 (en) | 2015-07-10 | 2021-01-12 | Abbott Diabetes Care Inc. | Systems, devices, and methods for meal information collection, meal assessment, and analyte data correlation |
DE202016009220U1 (en) | 2015-07-10 | 2024-07-09 | Abbott Diabetes Care, Inc. | Device and system for dynamic glucose profile response to physiological parameters |
EP4325222A2 (en) | 2016-03-04 | 2024-02-21 | Abbott Diabetes Care Inc. | Nad(p)-dependent responsive enzymes, electrodes and sensors, and methods for making and using the same |
US12234498B2 (en) | 2016-03-04 | 2025-02-25 | Abbott Diabetes Care Inc. | NAD(P)-dependent responsive enzymes, electrodes and sensors, and methods for making and using the same |
WO2017151952A1 (en) | 2016-03-04 | 2017-09-08 | Abbott Diabetes Care Inc. | Nad(p)-dependent responsive enzymes, electrodes and sensors, and methods for making and using the same |
USD1015366S1 (en) | 2020-07-29 | 2024-02-20 | Abbott Diabetes Care Inc. | Display screen or portion thereof with graphical user interface |
WO2022164940A1 (en) | 2021-01-26 | 2022-08-04 | Abbott Diabetes Care Inc. | Systems, devices, and methods related to ketone sensors |
WO2023110190A1 (en) | 2021-12-13 | 2023-06-22 | Heraeus Medical Gmbh | Tests and methods for detecting bacterial infection |
WO2024083429A1 (en) | 2022-10-20 | 2024-04-25 | Heraeus Medical Gmbh | Treatment of microbial infections diagnosed using the biomarker d-lactate |
EP4357778A1 (en) | 2022-10-20 | 2024-04-24 | Heraeus Medical GmbH | Treatment of microbial infections diagnosed using the biomarker d-lactate |
Also Published As
Publication number | Publication date |
---|---|
US20090229996A1 (en) | 2009-09-17 |
EP2092329A1 (en) | 2009-08-26 |
US8972198B2 (en) | 2015-03-03 |
WO2008054608A1 (en) | 2008-05-08 |
CA2667982A1 (en) | 2008-05-08 |
US20150168332A1 (en) | 2015-06-18 |
US20080102441A1 (en) | 2008-05-01 |
CN101573616A (en) | 2009-11-04 |
US7966131B2 (en) | 2011-06-21 |
US20110303539A1 (en) | 2011-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7822557B2 (en) | Analyte sensors and methods | |
US10921278B2 (en) | Slope-based compensation including secondary output signals | |
JP5039062B2 (en) | Temperature-corrected analyte determination in a biosensor system | |
US8083925B2 (en) | Analyte determination methods and devices | |
JP6448504B2 (en) | Slope-based correction | |
JP5121822B2 (en) | Abnormal output detection system for biosensor | |
CN102854232B (en) | There is the bio-sensor system of signal conditioning functions | |
US8545693B2 (en) | Analyte measurment method and system | |
US9244036B2 (en) | System and method for determination of a concentration of at least one interfering substance and correction of glucose concentration based on the concentration of the interfering substance | |
KR20150064112A (en) | System and method for determining hematocrit insensitive glucose concentrations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ABBOTT CARE DIABETES INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHEN, TING;FELDMAN, BENJAMIN;REEL/FRAME:018857/0885 Effective date: 20070124 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552) Year of fee payment: 8 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 12 |